Income statement revenue $801.7M (+23.5% YoY).Operating income $129.7M (+7.1% YoY).Pre-tax result $118.7M (+318.0% YoY).Net result $95M (+322.2% YoY).

Drug Delivery: $5.8M (-43.1% YoY)
International Omnipod: $251.8M (+35.5% YoY)
U.S.Omnipod: $544.1M (+20.1% YoY)
Research and development expenses: $88.1M (+20.0% YoY)
Selling, general and administrative expenses: $344.8M (+33.8% YoY)
Other expense: $11M (-88.1% YoY)
Income tax expense: $23.7M (+301.7% YoY)

Loading financials

Income statement income statement flow. Revenue $801.7M. Net result $95M.

Income statement revenue $801.7M (+23.5% YoY).Operating income $129.7M (+7.1% YoY).Pre-tax result $118.7M (+318.0% YoY).Net result $95M (+322.2% YoY).

Drug Delivery: $5.8M (-43.1% YoY)
International Omnipod: $251.8M (+35.5% YoY)
U.S.Omnipod: $544.1M (+20.1% YoY)
Research and development expenses: $88.1M (+20.0% YoY)
Selling, general and administrative expenses: $344.8M (+33.8% YoY)
Other expense: $11M (-88.1% YoY)
Income tax expense: $23.7M (+301.7% YoY)